Indivior Pharmaceuticals, Inc.
INDV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001625297
In the last 90 days, Indivior Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 1 sale; 337 institutions reported holding it in 13F filings for Q2 2026, worth $4.98B in total; Oaktree Capital is the only superinvestor holding it.
Key figures
- Insider buysLast 90 days, $108.0K in total
- 2
- Insider sellsLast 90 days, $764.6K in total
- 1
- 13F holdersQ2 2026, +51 vs. previous quarter
- 337
- 13F valueReported value at the end of Q2 2026
- $4.98B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding INDV, Q2 2026
1 superinvestor reports holding Indivior Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Oaktree Capital
Howard Marks
4.7%
Indivior Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 6,127,212
- Value
- $251.4M
Latest insider trades
Open-market purchases and sales by Indivior Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 (view filing)4:00 PM ET | Aug 27 | Same day | Anderson Woodrow DChief Accounting Officer | PPurchase | +1.50K | $35.69 | +$53.5K | +5.7%27.6K after | |
| Aug 5, 2026 (view filing)4:52 PM ET | Aug 5 | Same day | Anderson Woodrow DChief Accounting Officer | PPurchase | +1.50K | $36.28 | +$54.4K | +6.1%26.1K after | |
| Jul 13, 2026 (view filing)4:31 PM ET | Jul 10 | 3 days | Heidbreder ChristianChief Scientific Officer | SSale | −18.6K | $41.14 | −$764.6K | −8.2%209.3K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 11 | 1 day | Heidbreder ChristianChief Scientific Officer | SSale | −18.6K | $38.06 | −$707.4K | −7.5%227.9K after | 10b5-1 |
| Jun 10, 2026 (view filing) | Jun 8 | 2 days | Preblick RyanChief Financial Officer | SSale | −36.0K | $37.70 | −$1.36M | −11.2%284.8K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | Ryan BarbaraDirector | PPurchase | +8 | $31.09 | +$248.72 | +0.1%5.72K after | |
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Ryan BarbaraDirector | PPurchase | +31 | $32.56 | +$1.01K | +0.5%5.72K after | |
| Mar 11, 2026 (view filing) | Mar 6 | 5 daysLate | Kingsley Stuart ADirector | PPurchase | +940 | $31.87 | +$30.0K | +20.2%5.58K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Humphreys KeithDirector | PPurchase | +775 | $35.39 | +$27.4K | +15.4%5.80K after | 10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Ryan BarbaraDirector | PPurchase | +775 | $35.39 | +$27.4K | +65.2%1.96K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Indivior Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,709,432 | $767.6M | 0.01% | +167,212+0.9% | Added |
| Vanguard Portfolio Management LLC | 7,572,287 | $310.7M | 0.01% | −319,532−4.0% | Reduced |
| Oaktree Capital Management LPSuperinvestorOaktree Capital | 6,127,212 | $251.4M | 4.73% | −856,890−12.3% | Reduced |
| Vanguard Capital Management LLC | 5,495,486 | $225.5M | 0.00% | −91,090−1.6% | Reduced |
| State Street Corp | 4,992,071 | $204.8M | 0.01% | +88,078+1.8% | Added |
| Fuller & Thaler Asset Management, Inc. | 4,615,816 | $189.4M | 0.52% | +86,233+1.9% | Added |
| Two Seas Capital LP | 3,479,493 | $142.8M | 5.45% | −1,267,017−26.7% | Reduced |
| Morgan Stanley | 3,395,702 | $139.3M | 0.01% | −110,115−3.1% | Reduced |
| Franklin Resources Inc | 3,316,358 | $136.1M | 0.03% | +3,204,765+2,871.8% | Added |
| Geode Capital Management, LLC | 3,159,866 | $129.7M | 0.01% | +234,178+8.0% | Added |